Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?

Giovanni D. Aletti, Harry J. Long, Karl C. Podratz, William Arthur Cliby

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives: Clinicians often question when to start chemotherapy after patients undergo surgery for ovarian cancer. A major unproven concern is whether a long postoperative delay reduces the benefits of an extensive procedure and leads to disease progression. Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the "time to chemotherapy" (TTC) interval on survival. Methods: We retrospectively studied data from 218 patients with International Federation of Gynecology and Obstetrics stage IIIC or IV ovarian cancer (TNM stage T3c or T4) who were consecutively treated between January 1, 1994, and December 31, 1998. Results: Mean age at diagnosis was 64 years (range, 24-87 years; median, 65 years), and 206 patients received postoperative platinum-based chemotherapy. Mean TTC interval was 26 days (range, 7-79 days; median, 25 days). No correlation was found between operative time and TTC interval length (P = 0.99). Age and performance of rectosigmoidectomy were correlated with longer TTC interval (P = 0.009 and P = 0.005, respectively), but TTC was not a predictor of overall survival (odds ratio, 1.00; 95% confidence interval, 0.98-1.01; P = 0.85). Differences in TTC interval length (≤ 17 days, 18-26 days, 27-33 days, or ≥ 34 days) did not affect survival (P = 0.93). Even after categorizing patients by residual disease (< 1 cm or  ≥ 1 cm), no statistically significant effect of TTC on prognosis was identified. Conclusions: Concerns about the TTC interval should not be used to justify spending less time in the operative arena or using a more conservative approach for patients with advanced ovarian cancer.

Original languageEnglish (US)
Pages (from-to)212-216
Number of pages5
JournalGynecologic Oncology
Volume104
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Ovarian Neoplasms
Drug Therapy
Operative Time
Survival
Platinum
Gynecology
Obstetrics
Disease Progression
Odds Ratio
Confidence Intervals

Keywords

  • Chemotherapy timing
  • Ovarian cancer
  • Residual disease
  • Surgery

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? / Aletti, Giovanni D.; Long, Harry J.; Podratz, Karl C.; Cliby, William Arthur.

In: Gynecologic Oncology, Vol. 104, No. 1, 01.2007, p. 212-216.

Research output: Contribution to journalArticle

Aletti, Giovanni D. ; Long, Harry J. ; Podratz, Karl C. ; Cliby, William Arthur. / Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?. In: Gynecologic Oncology. 2007 ; Vol. 104, No. 1. pp. 212-216.
@article{b90a67c1d20f484b875277eee433a572,
title = "Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?",
abstract = "Objectives: Clinicians often question when to start chemotherapy after patients undergo surgery for ovarian cancer. A major unproven concern is whether a long postoperative delay reduces the benefits of an extensive procedure and leads to disease progression. Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the {"}time to chemotherapy{"} (TTC) interval on survival. Methods: We retrospectively studied data from 218 patients with International Federation of Gynecology and Obstetrics stage IIIC or IV ovarian cancer (TNM stage T3c or T4) who were consecutively treated between January 1, 1994, and December 31, 1998. Results: Mean age at diagnosis was 64 years (range, 24-87 years; median, 65 years), and 206 patients received postoperative platinum-based chemotherapy. Mean TTC interval was 26 days (range, 7-79 days; median, 25 days). No correlation was found between operative time and TTC interval length (P = 0.99). Age and performance of rectosigmoidectomy were correlated with longer TTC interval (P = 0.009 and P = 0.005, respectively), but TTC was not a predictor of overall survival (odds ratio, 1.00; 95{\%} confidence interval, 0.98-1.01; P = 0.85). Differences in TTC interval length (≤ 17 days, 18-26 days, 27-33 days, or ≥ 34 days) did not affect survival (P = 0.93). Even after categorizing patients by residual disease (< 1 cm or  ≥ 1 cm), no statistically significant effect of TTC on prognosis was identified. Conclusions: Concerns about the TTC interval should not be used to justify spending less time in the operative arena or using a more conservative approach for patients with advanced ovarian cancer.",
keywords = "Chemotherapy timing, Ovarian cancer, Residual disease, Surgery",
author = "Aletti, {Giovanni D.} and Long, {Harry J.} and Podratz, {Karl C.} and Cliby, {William Arthur}",
year = "2007",
month = "1",
doi = "10.1016/j.ygyno.2006.07.045",
language = "English (US)",
volume = "104",
pages = "212--216",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?

AU - Aletti, Giovanni D.

AU - Long, Harry J.

AU - Podratz, Karl C.

AU - Cliby, William Arthur

PY - 2007/1

Y1 - 2007/1

N2 - Objectives: Clinicians often question when to start chemotherapy after patients undergo surgery for ovarian cancer. A major unproven concern is whether a long postoperative delay reduces the benefits of an extensive procedure and leads to disease progression. Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the "time to chemotherapy" (TTC) interval on survival. Methods: We retrospectively studied data from 218 patients with International Federation of Gynecology and Obstetrics stage IIIC or IV ovarian cancer (TNM stage T3c or T4) who were consecutively treated between January 1, 1994, and December 31, 1998. Results: Mean age at diagnosis was 64 years (range, 24-87 years; median, 65 years), and 206 patients received postoperative platinum-based chemotherapy. Mean TTC interval was 26 days (range, 7-79 days; median, 25 days). No correlation was found between operative time and TTC interval length (P = 0.99). Age and performance of rectosigmoidectomy were correlated with longer TTC interval (P = 0.009 and P = 0.005, respectively), but TTC was not a predictor of overall survival (odds ratio, 1.00; 95% confidence interval, 0.98-1.01; P = 0.85). Differences in TTC interval length (≤ 17 days, 18-26 days, 27-33 days, or ≥ 34 days) did not affect survival (P = 0.93). Even after categorizing patients by residual disease (< 1 cm or  ≥ 1 cm), no statistically significant effect of TTC on prognosis was identified. Conclusions: Concerns about the TTC interval should not be used to justify spending less time in the operative arena or using a more conservative approach for patients with advanced ovarian cancer.

AB - Objectives: Clinicians often question when to start chemotherapy after patients undergo surgery for ovarian cancer. A major unproven concern is whether a long postoperative delay reduces the benefits of an extensive procedure and leads to disease progression. Our objectives were to evaluate the correlation between clinical and pathologic variables and to evaluate the effect of the "time to chemotherapy" (TTC) interval on survival. Methods: We retrospectively studied data from 218 patients with International Federation of Gynecology and Obstetrics stage IIIC or IV ovarian cancer (TNM stage T3c or T4) who were consecutively treated between January 1, 1994, and December 31, 1998. Results: Mean age at diagnosis was 64 years (range, 24-87 years; median, 65 years), and 206 patients received postoperative platinum-based chemotherapy. Mean TTC interval was 26 days (range, 7-79 days; median, 25 days). No correlation was found between operative time and TTC interval length (P = 0.99). Age and performance of rectosigmoidectomy were correlated with longer TTC interval (P = 0.009 and P = 0.005, respectively), but TTC was not a predictor of overall survival (odds ratio, 1.00; 95% confidence interval, 0.98-1.01; P = 0.85). Differences in TTC interval length (≤ 17 days, 18-26 days, 27-33 days, or ≥ 34 days) did not affect survival (P = 0.93). Even after categorizing patients by residual disease (< 1 cm or  ≥ 1 cm), no statistically significant effect of TTC on prognosis was identified. Conclusions: Concerns about the TTC interval should not be used to justify spending less time in the operative arena or using a more conservative approach for patients with advanced ovarian cancer.

KW - Chemotherapy timing

KW - Ovarian cancer

KW - Residual disease

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=33846073452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846073452&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.07.045

DO - 10.1016/j.ygyno.2006.07.045

M3 - Article

C2 - 17023033

AN - SCOPUS:33846073452

VL - 104

SP - 212

EP - 216

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -